RTC
ABBV icon

Real Talk Capital’s AbbVie ABBV Stock Holding History

Real Talk Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$462K Sell
2,125
-1,118
-34% -$248K 0.44% 47
2025
Q4 		$741K Sell
3,243
-880
-21% -$200K 0.74% 31
2025
Q3 		$955K Buy
4,123
+308
+8% +$62.7K 1.03% 21
2025
Q2 		$708K Sell
3,815
-29
-0.8% -$5.39K 0.85% 27
2025
Q1 		$805K Buy
3,844
+80
+2% +$15.6K 1.09% 21
2024
Q4 		$669K Buy
+3,764
New +$692K 0.88% 32

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Real Talk Capital's ABBV Position: Q1 2026 in Review

Real Talk Capital reduced its AbbVie (ABBV) stake by 34% in Q1 2026, selling an estimated $248K and leaving 2,125 shares worth $462K. The position accounts for 0.44% of the portfolio, ranked #47.

Real Talk Capital first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $955K in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Real Talk Capital held 2,125 shares of AbbVie worth $462K as of Q1 2026.
  • Real Talk Capital sold 1,118 AbbVie shares in Q1 2026, an estimated $248K.
  • AbbVie made up 0.44% of Real Talk Capital's portfolio in Q1 2026, its #47 holding.
  • Real Talk Capital first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • Real Talk Capital's AbbVie position peaked at $955K in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Real Talk Capital's 13F filing for Q1 2026, filed 15 May 2026.